Mar 22, 2021 ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
Feb 2, 2021 ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Nov 9, 2020 ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
Oct 23, 2020 ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants